Mithra Pharmaceuticals S.A.
MITRA.BR
Euronext Brussels0.22
EUR
- -
- -
Mithra Pharmaceuticals S.A.
MITRA.BR
(Euronext Brussels)
Recent
price
0.22
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Mithra Pharmaceuticals S.A. is a Belgian biotechnology company specializing in the development, manufacturing, and commercialization of pharmaceutical products focused on women's health. The company's core product offerings include contraceptive pills, hormone therapies for menopause, treatments for fertility, and complex therapeutics addressing hormone-dependent cancers. Mithra's flagship product is Estelle®, a combined oral contraceptive based on estetrol, which has completed phase III clinical trials and is commercially available. Another key product in development is Donesta®, an estetrol-based oral hormone therapy for menopause currently in late-stage clinical trials. The company also develops proprietary and over-the-counter pharmaceutical products including pregnancy vitamins, nutritional supplements, intimate care products, and contraceptive devices. Additionally, Mithra operates a contract development and manufacturing organization (CDMO) platform called Mithra CDMO, providing research, development, and manufacturing services to partners globally. Mithra's products and services are marketed in over 100 countries, with headquarters located in Liège, Belgium. In recent major developments, Mithra Pharmaceuticals filed for bankruptcy in mid-2024 and accordingly sold its shareholdings in two subsidiary companies along with rights to its female hormone drug portfolio to Hungarian pharmaceutical company Gedeon Richter for approximately €175 million. As part of this transaction, Gedeon Richter also assumed responsibilities for the ongoing development of Mithra’s menopause treatment candidate Donesta, which showed positive phase III results in 2023. The estetrol (E4) hormone therapy underlying these products is anticipated to gain regulatory approval in the US in 2024 and in the European Union in 2025. Despite bankruptcy proceedings, certain entities such as Mithra’s CDMO and Novalon SA remain under separate reorganization processes. Mithra has also delayed or put on hold R&D projects related to neurotherapy and wound healing but continues to pursue strategic collaborations and partnerships to support research in innovative women’s health therapeutics. Founded in 1999, Mithra Pharmaceuticals operates primarily within the pharmaceutical industry, focusing on healthcare segments of contraception, fertility, menopause, and hormone-dependent cancer treatments. The company serves a global customer base through its production and licensing agreements and has approximately 300 employees. Mithra's ongoing business transformation reflects a strategic shift toward partnering with larger pharmaceutical firms to advance its innovative hormone therapy portfolio while managing capital through asset sales and restructuring efforts. The company’s extensive product pipeline and technological platform underpin its mission to transform women’s health by providing new therapeutic options to improve quality of life. This comprehensive description incorporates Mithra's core products, service offerings, recent strategic changes including bankruptcy filing and asset sale, and operational context as of late 2025.